

CARDIOVASCULAR

PRODUCT	SPECS	EDMF (CTD)	USDMF	CEP
Ramipril	IP/BP/EP/USP	DMF Available	19714	R1-CEP 2006-040-REV 06
Ranolazine	In-house	DMF Available	21866	-
Quinapril HCL	EP/USP	DMF Available	19413	R1-CEP 2016-100 REV 00
Perindopril Arginine	In-house	DMF Available	-	-
Perindopril Tert-butylamine	EP/BP/USP	DMF Available	-	R1-CEP 2013-245-REV 02
Benazepril HCL	In-house	DMF Available	20097	R0-CEP 2023-055-REV 00
Enalapril Maleate	EP	DMF Available	-	-

ANTI-ASTHMATIC

Budesonide	IP/BP/EP/USP	DMF Available	20609	R1-CEP 2006-295-REV 04
Formoterol Fumarate Dihydrate	EP/BP/USP	DMF Available	-	R1-CEP 2013-220-REV 02
Fluticasone Propionate	IP/BP/EP/USP	DMF Available	22980	R1-CEP 2007-262-REV 03
Fluticasone Furoate	EP/USP	DMF Available	33955	CEP 2024-361-REV 00
Salmeterol Xinafoate	IP/EP/BP/USP	DMF Available	22054	CEP 2008-239-REV 05
Mometasone Furoate Monohydrate	EP/BP	DMF Available	23977	CEP 2018-303-REV-03
Ipratropium Bromide	IP/EP/BP/USP	DMF Available	21179	R1-CEP 2008-150-REV 03
Ciclesonide	In-house/EP	DMF Available	23650	CEP 2014-090-REV 02
Levalbuterol HCL	USP	DMF Available	20557	-
R-Salbutamol Sulphate	IP/In-house	DMF Available	-	-
Bambuterol HCL	IP/EP/BP	DMF Available	-	-
Montelukast Sodium	IP/BP/EP/USP	Validation 2026	-	-

ANTI-CANCER

Bicalutamide	EP/USP	DMF Available	20502	R1-CEP 2012-223-REV 01
Enzalutamide	USP	DMF Available	35618	-
Apalutamide	In-house	DMF Available	-	-
Palbociclib	In-house	DMF Available	41388	-
Ribociclib	In-house	Validation 2026	-	-
Ibrutinib	In-house	DMF Available	-	-
Nilotinib	In-house	DMF Available	42588	-
Ruxolitinib	In-house	Validation 2026	-	-
Osmertinib	In-house	Validation 2026	-	-
Venetoclax	In-house	DMF Available	-	-
Olaparib	In-house	Validation 2026	-	-
Azathioprine	BP/EP/USP	DMF Available	23038	R1-CEP 2014-030-REV 01
Mercaptopurine	IP/BP/EP/USP	DMF Available	22971	CEP 2021-275-REV 01
Mesna	EP/BP/USP	DMF Available	22664	R1-CEP 2009-127-REV 01
Ifosfamide	IP/BP/EP/USP	DMF Available	25081	-
Cyclophosphamide	IP/BP/EP/USP	DMF Available	37086	CEP 2025-325-REV 00

ANTI-COAGULANT

Apixaban	In-house	DMF Available	35969	-
Rivaroxaban	In-house/EP	DMF Available	-	-
Edoxaban Tosylate	In-house	Validation 2026	-	-

- Products protected by patents are developed solely for the R&D purposes intended to support regulatory submissions.
- It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).
- Intermediates of above API's will be available.

For Enquiries:

+91-22-69436100

api@aartipharmalabs.com

www.aartipharmalabs.com

ANTI-DIABETIC

PRODUCT

	SPECS	EDMF (CTD)	USDMF	CEP
Empagliflozin	In-house	DMF Available	42587	-
Canagliflozin	In-house	DMF Available	-	-
Dapagliflozin Propanediol	In-house	Validation 2026	-	-
Sitagliptin Phosphate Monohydrate	USP/EP	DMF Available	-	-
Sitagliptin Phosphate Anhydrous	In-house	DMF Available	42081	-
Sitagliptin HCL	In-house	DMF Available	-	-

OVERACTIVE BLADDER

Mirabegron	In-house	DMF Available	42590	CEP 2025-435 (Applied)
------------	----------	---------------	-------	------------------------

CNS AGENT/ANTI-DEPRESSION

Venlafaxine HCL	BP/EP/USP	DMF Available	19879	R1-CEP 2006-183-REV 03
Venlafaxine HCL Polymorph B	BP/EP/USP	DMF Available	28433	R1-CEP 2009-082-REV 02
Quetiapine Fumarate	EP/USP	DMF Available	21336	R0-CEP 2019-291-REV 02
Bupropion HCL	EP/ BP/ USP	DMF Available	27204	-
Vortioxetine HBr	In-house	DMF Available	-	-

SKIN CARE

Mometasone Furoate Anhydrous	BP/EP/USP	DMF Available	33174	R1-CEP 2007-302-REV 03
Desonide	In-house	DMF Available	22963	-
Adapalene	BP/EP/USP	DMF Available	22709	CEP-2022-158 - REV 01

ARTHRITIS

Tofacitinib Citrate	In-house	Validation 2026	-	-
---------------------	----------	-----------------	---	---

CALCIMIMETIC

Cinacalcet	IP/In-house	DMF Available	-	-
------------	-------------	---------------	---	---

DECONGESTANT

Phenylephrine	EP/BP/USP/IP	DMF Available	42589	-
---------------	--------------	---------------	-------	---

ANTI-THALISMATIC

Deferiprone	In-house/EP	DMF Available	39766	CEP 2024-124 REV 00
-------------	-------------	---------------	-------	---------------------

OPHTHALMOLOGIC

Loteprednol Etabonate	In-house	DMF Available	26249	-
-----------------------	----------	---------------	-------	---

ANALGESIC

Diflunisal	USP	DMF Available	24762	-
------------	-----	---------------	-------	---

XANTHINE DERIVATIVES

Caffeine	IP/BP/EP/USP/FCC	DMF Available	41282	CEP 2025-086 (Applied)
Theophylline	IP/BP/EP/USP	DMF Available	-	-
Aminophylline	IP/BP/EP/USP	DMF Available	-	-
Etophylline	IP/BP/EP/USP	DMF Available	-	-

UPCOMING MOLECULES

API Name	Therapeutic Category	API Name	Therapeutic Category
Darolutamide	Anti-cancer	Acalabrutinib	Anti-cancer
Abemaciclib	Anti-cancer	Ertugliflozin	Anti-diabetic
Relugolix	Anti-cancer	Upadacitinib	Arthritis
Zanubrutinib	Anti-cancer	Finerenone	Nephrology
Niraparib	Anti-cancer	Vibegron	Overactive Bladder

- Products protected by patents are developed solely for the R&D purposes intended to support regulatory submissions.
- It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).
- Intermediates of above API's will be available.

For Enquiries:

+91-22-69436100

api@aartipharma.com

www.aartipharma.com